Adverts

Open Access Articles- Top Results for Atagabalin

Atagabalin

</th></tr>
Atagabalin
File:Atagabalin structure.png
Systematic (IUPAC) name
[(3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid
Clinical data
Identifiers
223445-75-8 7pxN
None
PubChem CID 9794485
ChemSpider 7970252 7pxY
UNII JT7957Q2FB 7pxY
ChEMBL CHEMBL593430 7pxY
Chemical data
Formula C10H19NO2
185.263 g/mol
 14pxN (what is this?)  (verify)

Atagabalin (PD-0200,390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2).[1] It was under development as a treatment for insomnia,[2][3][4] but was discontinued following unsatisfactory trial results.

See also

References

  1. ^ Blakemore DC, Bryans JS, Carnell P, Carr CL, Chessum NE, Field MJ, Kinsella N, Osborne SA, Warren AN, Williams SC (January 2010). "Synthesis and in vivo evaluation of bicyclic gababutins". Bioorganic & Medicinal Chemistry Letters 20 (2): 461–4. PMID 20005103. doi:10.1016/j.bmcl.2009.11.118. 
  2. ^ Corrigan B, Feltner DE, Ouellet D, Werth JL, Moton AE, Gibson G (August 2009). "Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit". British Journal of Clinical Pharmacology 68 (2): 174–80. PMC 2767279. PMID 19694735. doi:10.1111/j.1365-2125.2009.03444.x. 
  3. ^ Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA (May 2011). "Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: Basic characterization and drug pharmacology". Brain Research 1401: 1–9. PMID 21664606. doi:10.1016/j.brainres.2011.05.025. 
  4. ^ Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (June 2011). "Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models". Pharmaceutical Research 28 (10): 2610–27. PMID 21681607. doi:10.1007/s11095-011-0490-x. 



Lua error in package.lua at line 80: module 'Module:Buffer' not found.